Previous Article | Next Article 
Applied and Environmental Microbiology, May 2000, p. 1928-1932, Vol. 66, No. 5
0099-2240/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Antimicrobial Peptides Protect Coho Salmon from
Vibrio anguillarum Infections
X.
Jia,1
A.
Patrzykat,1
R. H.
Devlin,2
P. A.
Ackerman,3
G. K.
Iwama,3 and
R. E. W.
Hancock1,*
Department of Microbiology and Immunology,
University of British Columbia, Vancouver, British Columbia, Canada V6T
1Z31; Fisheries and Oceans Canada, West
Vancouver, British Columbia, Canada V7V 1N62;
and Faculty of Agricultural Science, University of British
Columbia, Vancouver, British Columbia, Canada V6T 2A23
Received 6 December 1999/Accepted 3 February 2000
 |
ABSTRACT |
Fish losses from infectious diseases are a significant problem in
aquaculture worldwide. Therefore, we investigated the ability of
cationic antimicrobial peptides to protect against infection caused by
the fish pathogen Vibrio anguillarum. To identify effective peptides for fish, the MICs of certain antimicrobial peptides against
fish pathogens were determined in vitro. Two of the most effective
antimicrobial peptides, CEME, a cecropin-melittin hybrid peptide, and
pleurocidin amide, a C-terminally amidated form of the natural flounder
peptide, were selected for in vivo studies. A single intraperitoneal
injection of CEME did not affect mortality rates in juvenile coho
salmon infected with V. anguillarum, the causative agent of
vibriosis. Therefore, the peptides were delivered continuously using
miniosmotic pumps placed in the peritoneal cavity. Twelve days after
pump implantation, the fish received intraperitoneal injections of
V. anguillarum at a dose that would kill 50 to 90% of the
population. Fish receiving 200 µg of CEME per day survived longer and
had significantly lower accumulated mortalities (13%) than the control
groups (50 to 58%). Fish receiving pleurocidin amide at 250 µg per
day also survived longer and had significantly lower accumulated
mortalities (5%) than the control groups (67 to 75%). This clearly
shows the potential for antimicrobial peptides to protect fish against
infections and indicates that the strategy of overexpressing the
peptides in transgenic fish may provide a method of decreasing
bacterial disease problems.
 |
INTRODUCTION |
During the last decades,
gene-encoded cationic antimicrobial peptides have been identified in
virtually all species of life, including bacteria, plants, vertebrates,
invertebrates, and mammals. Many of these peptides have been shown to
play roles in host defenses, providing local nonspecific protection
against infectious microbes. Such a role is assisted by the broad
spectrum of activity against bacteria, fungi, and/or enveloped viruses
and the rapid action of these cationic peptides. Well-known examples of
cationic antimicrobial peptides are the cecropins, melittins, magainin,
and defensins (8).
Protection of fish against infectious diseases is a major challenge in
aquaculture worldwide, and losses due to infectious diseases limit
profitability. The use of antibiotics and vaccination has partially
alleviated this problem. However antibiotic use has raised concerns of
antibiotic resistance development and antibiotic residues in fish.
Vaccines are not available for all of the fish pathogens, and
vaccinations can involve stressful handling of the animals. One
alternative strategy would be to develop disease-resistant fish
strains. Considerable evidence has shown that the ectopic expression of
genes encoding peptides with in vitro antimicrobial activity can result
in increased resistance to fungal and bacterial pathogens in transgenic
plants (2, 9, 12, 20) and mice (18). Those
peptides could prove to be useful tools for the genetic engineering of
disease resistance in transgenic fish. Kelly et al. (10)
showed that LSB-37 and Shiva-1, two synthetic derivatives of insect
-helical peptides derived from native cecropin B, were effective
against a wide variety of gram-negative fish pathogens in vitro.
Furthermore, LSB-37 was able to control Edwardsiella ictaluri infections in channel catfish (11).
Relatively few natural antimicrobial peptides have been discovered in
fish. Pardaxin, originally identified as a shark-repellent peptide from
Moses sole fish, is a polypeptide toxin that has antimicrobial
activity (16). However, that peptide does not possess an amphipathic structure with multiple positive charges like
other antimicrobial cationic peptides and is cytotoxic to mammalian
cells. Most recently, misgurin (17) and pleurocidin (3) were found in loach (Misgurnus
anguillicaudatus) and flounder (Pleuronectes
americanus), respectively. Misgurin is a 21-amino-acid peptide
with in vitro antimicrobial activity against a broad spectrum of
microorganisms and has no significant hemolytic activity
(17). Pleurocidin is a 25-residue linear antimicrobial
peptide found in the skin mucous secretions of the winter flounder.
Pleurocidin has been shown to exert broad-spectrum activity against a
wide range of gram-positive and gram-negative bacteria (3).
It has high amino acid sequence homology with two other antimicrobial peptides, dermaseptin from the skin of the arboreal frog
(15) and ceratotoxin from the Mediterranean fruit fly
(14). All three of these peptides have been proposed to form
amphipathic
-helices (3, 13, 15).
We investigated the antimicrobial activities of a variety of peptides
to identify those that are active against fish pathogens. Two of the
more-effective peptides, CEME and amidated pleurocidin, were
demonstrated to have the ability to protect coho salmon
(Oncorhynchus kisutch) against Vibrio anguillarum
infection in vivo.
 |
MATERIALS AND METHODS |
Bacterial strains and growth media.
The following bacterial
strains were used for testing antimicrobial activity. Field isolates of
salmonid pathogens Aeromonas salmonicida and V. anguillarum were satisfactorily identified and kindly provided by
Julian Thornton, Microtek International Inc., Victoria, British
Columbia, Canada. Pseudomonas aeruginosa strains K799
(parent strain) and Z61 (antibiotic supersusceptible) were described by
Angus et al. (1). The parent strain (14028s) and a
defensin-supersusceptible strain (MS7953s) of Salmonella enterica serovar Typhimurium were described by Fields et al.
(6). Staphylococcus epidermidis C621 was a human
clinical isolate obtained from A. Chow, University of British Columbia
(UBC). All strains of P. aeruginosa, S. enterica
serovar Typhimurium, and S. epidermidis were maintained at
37°C in Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.),
while the fish bacteria were maintained at 16°C in tryptic soy broth
(Difco; 5 g of NaCl/liter) or tryptic soy broth supplemented with
NaCl to a total concentration of 10 g/liter. All strains were stored at
70°C until they were thawed for use and subcultured daily.
Synthesis of peptides.
All peptides were produced using
9-fluorenylmethoxy chemistry by the Nucleic Acid and Protein Services,
UBC, Vancouver, Canada. Sequences of the new peptides presented here
are included in Table 1. The remaining
peptide sequences were as described by Wu et al. (22).
In vitro activity.
The antimicrobial activities of selected
antimicrobial peptides were determined as MICs using the modified
microtiter broth dilution method (22). Bacteria were grown
overnight to mid-logarithmic phase as described above and diluted to
give a final inoculum size of 106 CFU/ml. A suspension of
10 µl of the bacteria was added to each well of a 96-well plate and
incubated overnight at the appropriate temperature. Inhibition was
defined as growth less than or equal to one-half of the growth observed
in control wells, where no peptide was added.
Animals.
Coho salmon were obtained from the Chehalis River
of British Columbia and were maintained at 10°C in city water
dechlorinated with sodium thiosulfate (free flowing at 1 liter/min in
the winter and 2 liters/min in the summer), unless otherwise stated.
The fish were kept in a 70-liter tank and fed ad libitum by hand twice a day with a commercial diet.
In vivo experiments.
For single-injection studies, V. anguillarum was grown overnight at room temperature on tryptic soy
agar (supplemented with 15 g of NaCl/liter) plates. On the day of
the experiment, several colonies were collected and suspended in
sterile peptone-saline containing 1 g of Bacto Peptone (Sigma
Chemical Co., St. Louis, Mo.) and 8.5 g of NaCl/liter. Juvenile
coho salmon (approximately 16 to 18 g) were anesthetized with
0.01% ethyl m-aminobenzoate methanesulfonate (MS 222) in
0.02% sodium bicarbonate and received either peptone-saline alone,
CEME (200 µl of a 5-mg/ml concentration in peptone-saline) alone,
bacteria (100 µl of a suspension of 106/ml) alone, or a
combination of peptides and bacteria, separately injected
intraperitoneally. Fish were maintained in a 70-liter tank at
approximately 10°C. Mortality was recorded daily.
To mimic physiological conditions, miniosmotic pumps (model 1007D;
Alzet Corporation, Palo Alto, Calif.) were used to continuously
deliver
test agents at a controlled rate into fish. To increase
its solubility,
before being transferred into the osmotic pumps,
CEME was dissolved in
0.129 mM citric acid (2.45 mg/100 µl/pump
for the 80-µg/day group
and 6.14 mg/100 µl/pump for the 200-µg/day
group). Alternatively,
pleurocidin amide was dissolved in fish
saline (0.85% NaCl) and loaded
into the osmotic pumps (7.67 mg/100
µl/pump, 250 µg/day). Juvenile
coho salmon (approximately 20 g)
were divided into three treatment
groups: bacterial injection
alone (12 fish); installation of osmotic
pumps containing saline,
followed by bacterial injection (12 fish); and
a combination of
installation of osmotic pumps containing CEME followed
by bacterial
injection (18 fish). The fish were anesthetized as
described above,
and miniosmotic pumps with a pumping rate of 0.136 µl/h were implanted
into the peritoneal cavity. Briefly, the fish
were anesthetized
and put on a wet pad. A small midline incision of the
lower abdomen
was made to allow the insertion of the pump. The cut was
sutured
with one stitch and covered with tissue glue. Heaters were
placed
in the fish tanks to maintain water temperatures between 11 and
12°C. Pumps were filled with concentrated peptide as described
above
to deliver approximately 80 µg of peptide/day to fish over
a 30-day
period. Twelve days after pump implantation, the fish
received
intraperitoneal injections of
V. anguillarum (10,000
CFU/fish). Mortalities were recorded daily. For CEME, the experiment
was also repeated at a higher peptide dose of 200 µg/day (12 fish
for
each control group and 15 for the peptide group). The same
procedure
was used in the pleurocidin experiment (250 µg/day),
but with 12 fish
for each control group and 19 fish for the peptide
group. In all
experiments, fish were treated in a humane fashion
under the guidelines
of the Canadian Council for Animal
Care.
Statistics.
The accumulated mortalities are presented as
percentages. Differences between the mortalities were analyzed using
Fisher's exact test.
 |
RESULTS |
In vitro activities of cationic antimicrobial peptides.
Fish
pathogens A. salmonicida and V. anguillarum
were selected since they are common causes of infections in coho
salmon and rainbow trout reared on fish farms. As shown in Table
2, several
-helical peptides
related to CEME showed excellent activity against both A. salmonicida and V. anguillarum (MIC = 1 to 2 µg/ml), but not CP26, which was less effective against V. anguillarum. The extended 13-amino-acid peptide indolicidin and
its variant CP11-CN, as well as the cyclic 12-amino-acid peptide
bactenecin, had less activity against both pathogens than CEME. The
cyclic 10-amino-acid
-structured peptide gramicidin S exhibited
moderate activity against the fish pathogens.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Activity of antimicrobial peptides against fish pathogens
and other gram-negative bacteria and S. epidermidis
|
|
Eight derivatives of the two fish peptides pleurocidin and misgurin and
sequence homologues of pleurocidin, dermaseptin, and
ceratotoxin were
constructed. The primary structures of these
variants and their parent
molecules are depicted in Table
1.
Antimicrobial activities of all the
peptides against a range of
bacteria, including the fish pathogens,
were tested and are shown
in Table
2. The addition of lysine to the N
terminus of pleurocidin
(peptide P-1) did not significantly change the
antimicrobial activity.
However, the amidation of both pleurocidin and
P-1 substantially
enhanced their antimicrobial activities to a level
essentially
comparable to that of unamidated CEME. A hybrid of
pleurocidin
and dermaseptin (P-DER) had more antibacterial activity
than unamidated
pleurocidin, whereas a hybrid of pleurocidin and
ceratotoxin (P-CER)
had reduced activity. Misgurin alone was inactive
against the
bacteria tested. When misgurin was combined as a hybrid
with ceratotoxin,
the resulting peptide (CER-M) remained quite
inactive. However,
hybrids of pleurocidin (P-M) or dermaseptin
(DER-M) with misgurin
showed antibacterial activities approaching
those of pleurocidin.
These activities were compared to those of
cationic antibiotic
polymyxin B (a lipopeptide) and gentamicin, which
exhibited excellent
activity against some bacteria but less activity
than CEME and
pleurocidin amide against other bacteria. The MICs for
the PhoP
and -Q
S. enterica serovar Typhimurium mutant
MS7953s (defensin
supersusceptible) were 8- to 64-fold lower than those
for its
parent strain, whereas MICs of only a few peptides for
outer-membrane-altered
P. aeruginosa strain Z61 were lower
than those for its parent
strain (Table
2).
Protection against fish infections.
As described above, the
antimicrobial peptides CEME and pleurocidin amide were among the most
effective antimicrobial peptides tested against the fish pathogens
V. anguillarum and A. salmonicida in vitro.
Therefore, these two peptides were chosen for in vivo protection
studies. In the first experiment, the in vivo effect of CEME was tested
by single injections of 1 mg per fish. No fish died during the 10-day
trial in either the peptone-saline or the peptide control group (Fig.
1), suggesting that CEME did not
have a toxic effect on fish. However, fish injected with only
V. anguillarum had 60% mortality, while 82% of fish which
received CEME after the bacterial infection died. Although
slightly higher mortality in the group receiving peptide combined with
bacteria than in the group receiving bacteria alone was observed, the
difference was not significant (P = 0.3).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of a single CEME injection on V. anguillarum-infected salmon. CEME and V. anguillarum
were injected concurrently (CEME+Vang). The control groups were
injected with the bacteria alone (Vang only), the peptide alone (CEME
only), or peptone-saline alone (saline control). Each infected fish
received approximately 10,000 CFU of V. anguillarum. The
CEME injection was 1 mg/fish.
|
|
Since a single injection of CEME into coho salmon did not protect fish
from
V. anguillarum infection, we utilized constant
delivery
of peptides with miniosmotic pumps. In the studies involving
treatment
with a low dosage of CEME (80 µg/day), mortalities were
first noticed
on day 3 for the groups injected with bacteria without
peptide
treatment and for the group which received saline osmotic
pumps as well
as bacteria (Fig.
2A). There was no
difference in
accumulated mortality between the control groups
receiving bacterial
injection alone and the group receiving saline via
the osmotic
pump plus bacterial injection (92% for both of them;
P = 0.5).
However, mortalities were delayed for the
group receiving a lower
dose of CEME via the osmotic pump (first
noticed on day 5), and
this group had a relative longer survival time
and lower mortalities
than the other two groups (67%) although the
difference was not
significant (
P = 0.1). For the
high-dosage experiment (200 µg
of CEME/day), accumulated mortalities
were not significantly different
between the control group injected
with bacteria alone and the
group receiving bacterial injection and
saline via the pump (58
versus 50%, respectively;
P = 1) (Fig.
2B). However for the group
treated with CEME, the
accumulated mortality after bacterial injection
was significantly
reduced (13%;
P = 0.007). Some variation in
the
kinetics of killing in control animals was observed, possibly
due to
differences in the actual inocula and/or the age of the
fish in these
experiments. This, however, would not affect the
integrity of these
experiments since each set of controls was
injected with a bacterial
inoculum identical to that used in the
respective CEME-treated group.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
Protection of V. anguillarum-infected salmon
by CEME delivered via osmotic pump. CEME was constantly administered at
the level of 80 µg/day (A) and 200 µg/day (B) into coho salmon
though the use of implanted miniosmotic pumps with a pumping rate of
0.136 µl/h (CEME pump). The control groups (control) were injected
with bacteria alone. The pump control groups (pump control) were
implanted with osmotic pumps containing saline only. The temperature of
the tank water was controlled to maintain the constant pumping rate.
Twelve days after pump implantation, each fish was challenged with
approximately 10,000 CFU of V. anguillarum.
|
|
The above study was also performed using pleurocidin amide. Mortalities
were first noticed on day 3 for the group injected
with bacteria alone
and on day 5 for the group which received
saline via osmotic pumps as
well as bacterial injections (Fig.
3).
However, there was no significant difference in mortality
between the
group which did not have implanted osmotic pumps and
the group with the
saline osmotic pump (67 versus 75%, respectively;
P = 0.6). Only 1 out of 19 fish died (on day 6) in the group receiving
250 µg of pleurocidin amide/day via osmotic pump over the 30 days
of
this experiment. The accumulated mortality was thus dramatically
and
significantly (
P = 0.0002) reduced to 5% compared with
75%
for the saline pump control group.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 3.
The ability of pleurocidin amide to protect coho salmon
from a lethal challenge of V. anguillarum. The peptide was
continuously delivered into fish by a miniosmotic pump, implanted
intraperitoneally, at a pumping rate of 0.136 µl/h (pleurocidin
pump). In the peptide group each fish received pleurocidin amide at
approximately 250 µg/day. The control group received bacterial
injections only. Fish in the pump control group were implanted with
osmotic pumps containing saline only. The water temperature of the tank
was controlled to maintain the pumping rate. Twelve days of
equilibrating time elapsed before the fish were challenged with
approximately 10,000 CFU of V. anguillarum. The accumulated
mortalities were determined over 30 days.
|
|
 |
DISCUSSION |
This study has led to the encouraging finding of in vivo efficacy
of certain antimicrobial peptides against bacterial infections. It was
previously shown that two synthetic antimicrobial peptide derivatives
of the naturally occurring insect peptide cecropin B had significant in
vitro activity against bacterial pathogens of fish (10). Due
to differences in methodology between the study of Kelly et al. and the
present study, it is not possible to perform exact comparisons.
However, in general agreement with Kelly et al., we found that CEME, a
hybrid of two insect antimicrobial peptides which has both in vitro and
in vivo activity against animal pathogens (21), was also
very effective in killing two common pathogens of coho salmon, V. anguillarum and A. salmonicida. These findings raised
the possibility of utilizing these ectopic peptides through production
in transgenic animals, as has been previously done in plants and mice,
to enhance disease resistance in aquaculture. Although some
-helical
peptides related to CEME also had excellent activity, other natural
peptides (including cattle neutrophil indolicidin and bactenecin and
bacterial gramicidin S) had a lower potency against fish pathogens. For
this reason, and to probe the potential advantages offered by
fish-derived peptides, we turned to the flounder-derived peptide
pleurocidin (3).
Pleurocidin was found in winter flounder skin mucus and was shown to be
active against both gram-negative and gram-positive bacteria in fish
(3). Pleurocidin amide, a C-terminally amidated form, was
designed in our laboratory and was found to be more active than the
native peptide against different groups of bacteria, including the two
fish pathogens V. anguillarum and A. salmonicida. We also studied other peptides, including the fish peptide misgurin (which in our hands was inactive), an N-terminally extended version of
pleurocidin (P-1), and some hybrids with misgurin, as well as insect
and frog peptides related to pleurocidin.
In an attempt to improve the antimicrobial activity of pleurocidin and
its related peptides, an effort to design and synthesize a series of
different peptide constructs was also made. All three cationic peptide
constructs with improved antimicrobial activities (P-DER, P-CN, and
P-1-CN) were C-terminally amidated derivatives of pleurocidin.
C-terminal amidation has been previously shown to improve the
antimicrobial activity of many peptides (5, 16). The
improved activities may relate to better lipopolysaccharide binding
leading to improved self-promoted uptake across the outer membrane, as
demonstrated for the indolicidins (5). Perhaps most
surprising was the finding that in our studies the chemically synthesized misgurin exhibited no significant antimicrobial activity and that C-terminal misgurin hybrids showed reduced activities compared
to their pleurocidin equivalents. Also, it appeared that the
substitution of the N terminus of pleurocidin with the N terminus of
dermaseptin had no effect on antimicrobial activity, while the
substitution with the N terminus of ceratotoxin decreased this
activity. While certain constructs offered some activity against fish
and other pathogens, particularly P-DER and P-1 amide, none had
sufficient advantages over CEME and pleurocidin amide to merit
follow-up in vivo studies.
We chose CEME and pleurocidin amide to investigate the potential
efficacy of peptides in vivo. Kelly et al. (11) previously found that a single intraperitoneal injection of their peptide LSB-37
did not have a significant effect on survival but that when the peptide
was administered over a longer period using osmotic pumps it
significantly reduced mortality from E. ictaluri infections of channel catfish (11). Similarly, in our hands, a single
injection of CEME did not have any effect, but constant delivery of the peptide via an implanted miniosmotic pump significantly delayed and
reduced mortality in V. anguillarum-infected fish. It
appears that better protection was obtained when a higher level of
peptide was used in protection studies, suggesting that protection was dose dependent. Constant administration of pleurocidin amide also protected coho salmon from a lethal challenge with V. anguillarum, with the accumulated mortality being dramatically
reduced from 75 to 5%. These data are consistent with an important
role for fish peptides as a part of the fish nonspecific immune
response to infections, as inferred for other animals, including
insects, and plants. These results indicate that antimicrobial
peptides are not particularly effective in single treatments and that
constant administration over a certain period may be necessary to make this therapeutic approach successful. While osmotic pumps
are clearly not a feasible option in terms of protection of fish
from the threats of disease associated with aquaculture, they do mimic the physiological conditions in the bodies of transgenic animals engineered to overexpress peptides. In this regard, the finding that
fish peptides are significantly protective is very encouraging because
it has been demonstrated that genes derived from as close a species as
possible to the host are most efficiently expressed in transgenic
fish (4). The best choice would then be to utilize genes
encoding fish antimicrobial peptides to produce disease-resistant fish.
Overall, these studies demonstrate that CEME and pleurocidin amide are
potent antimicrobial agents with in vivo activity against the pathogen
V. anguillarum in coho salmon. Therefore, great
potential exists for the development of disease-resistant
transgenic fish using peptide genes. These agents may be powerful tools
for preventing disease outbreaks in aquaculture and
enhancement-oriented production systems.
 |
ACKNOWLEDGMENTS |
This work was funded by separate grants from the Canadian
Bacterial Diseases Network to R.E.W.H. and G.K.I. X.J. was a BC Science Council industrial postdoctoral fellow, sponsored by Microtech International Inc., Saanichton, British Columbia, Canada. R.E.W.H. was
a recipient of the Medical Research Council of Canada Distinguished Scientist Award. This study was also supported by a grant from Fisheries and Oceans of Canada National Biotechnology Strategy to
R.H.D.
The technical assistance of Ellen Teng is gratefully acknowledged.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3. Phone: (604) 822-2682. Fax: (604)
822-6041. E-mail: bob{at}cmdr.ubc.ca.
 |
REFERENCES |
| 1.
|
Angus, B. L.,
A. M. Carey,
D. A. Caron,
A. M. Kropinski, and R. E. Hancock.
1982.
Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild type with an antibiotic-supersusceptible mutant.
Antimicrob. Agents Chemother.
21:299-309[Abstract/Free Full Text].
|
| 2.
|
Broglie, K.,
I. Chet,
M. Holliday,
R. Cressman,
P. Biddle,
C. Knowlton,
C. J. Mauvai, and R. Broglie.
1991.
Transgenic plants with enhanced resistance to the fungal pathogen Rhizoctonia solani.
Science
254:1194-1197[Abstract/Free Full Text].
|
| 3.
|
Cole, A. M.,
P. Weis, and G. Diamond.
1997.
Isolation and characterization of pleurocidin, an antimicrobial peptide in the skin secretions of winter flounder.
J. Biol. Chem.
272:12008-12013[Abstract/Free Full Text].
|
| 4.
|
Devlin, R. H.
1997.
Transgenic animals: generation and use.
Harwood Academic Publishers, Amsterdam, The Netherlands.
|
| 5.
|
Falla, T. J.,
D. N. Karunaratne, and R. E. W. Hancock.
1996.
Mode of action of the antimicrobial peptide indolicidin.
J. Biol. Chem.
271:19298-19303[Abstract/Free Full Text].
|
| 6.
|
Fields, P. I.,
E. A. Groisman, and F. Heffron.
1989.
A Salmonella locus that controls resistance to microbicidal proteins from phagocytic cells.
Science
243:1059-1062[Abstract/Free Full Text].
|
| 7.
|
Friedrich, C.,
M. G. Scott,
N. Karunaratne,
H. Yan, and R. E. Hancock.
1999.
Salt-resistant alpha-helical cationic antimicrobial peptides.
Antimicrob. Agents Chemother.
43:1542-1548[Abstract/Free Full Text].
|
| 8.
|
Hancock, R. E., and R. Lehrer.
1998.
Cationic peptides: a new source of antibiotics.
Trends Biotechnol.
16:82-88[CrossRef][Medline].
|
| 9.
|
Jach, G.,
B. Gornhardt,
J. Mundy,
J. Logemann,
E. Pinsdorf,
R. Leah,
J. Schell, and C. Maas.
1995.
Enhanced quantitative resistance against fungal disease by combinatorial expression of different barley antifungal proteins in transgenic tobacco.
Plant J.
8:97-109[CrossRef][Medline].
|
| 10.
|
Kelly, D.,
W. R. Wolters, and J. M. Jaynes.
1990.
Effect of lytic peptides on selected fish bacterial pathogens.
J. Fish Dis.
13:317-321.
|
| 11.
|
Kelly, D. G.,
W. R. Wolters,
J. M. Jaynes, and J. C. Newton.
1993.
Enhanced disease resistance to enteric septicemia in channel catfish, Ictalurus punctatus, administered lytic peptide.
J. Appl. Aquacult.
3:25-34.
|
| 12.
|
Liu, D.,
K. G. Raghothama,
P. M. Hasegawa, and R. A. Bressan.
1994.
Osmotin overexpression in potato delays development of disease symptoms.
Proc. Natl. Acad. Sci. USA
91:1888-1892[Abstract/Free Full Text].
|
| 13.
|
Marchini, D.,
P. C. Giordano,
R. Amons,
L. F. Bernini, and R. Dallai.
1993.
Purification and primary structure of ceratotoxin A and B, two antibacterial peptides from the female reproductive accessory glands of the medfly Ceratitis capitata (Insecta:Diptera).
Insect Biochem. Mol. Biol.
23:591-598[CrossRef][Medline].
|
| 14.
|
Marchini, D.,
A. G. Manetti,
M. Rosetto,
L. F. Bernini,
J. L. Telford,
C. T. Baldari, and R. Dallai.
1995.
cDNA sequence and expression of the ceratotoxin gene encoding an antibacterial sex-specific peptide from the medfly Ceratitis capitata (diptera).
J. Biol. Chem.
270:6199-6204[Abstract/Free Full Text].
|
| 15.
|
Mor, A.,
V. H. Nguyen,
A. Delfour,
D. Migliore-Samour, and P. Nicolas.
1991.
Isolation, amino acid sequence, and synthesis of dermaseptin, a novel antimicrobial peptide of amphibian skin.
Biochemistry
30:8824-8830[CrossRef][Medline].
|
| 16.
|
Oren, Z., and Y. Shai.
1996.
A class of highly potent antibacterial peptides derived from pardaxin, a pore-forming peptide isolated from Moses sole fish Pardachirus marmoratus.
Eur. J. Biochem.
237:303-310[Medline].
|
| 17.
|
Park, C. B.,
J. H. Lee,
I. Y. Park,
M. S. Kim, and S. C. Kim.
1997.
A novel antimicrobial peptide from the loach, Misgurnus anguillicaudatus.
FEBS Lett.
411:173-178[CrossRef][Medline].
|
| 18.
|
Reed, W. A.,
P. H. Elzer,
F. M. Enright,
J. M. Jaynes,
J. D. Morrey, and K. L. White.
1997.
Interleukin 2 promoter/enhancer controlled expression of a synthetic cecropin-class lytic peptide in transgenic mice and subsequent resistance to Brucella abortus.
Transgenic Res.
6:337-347[CrossRef][Medline].
|
| 19.
|
Scott, M. G.,
H. Yan, and R. E. Hancock.
1999.
Biological properties of structurally related alpha-helical cationic antimicrobial peptides.
Infect. Immun.
67:2005-2009[Abstract/Free Full Text].
|
| 20.
|
Terras, F. R.,
K. Eggermont,
V. Kovaleva,
N. V. Raikhel,
R. W. Osborn,
A. Kester,
S. B. Rees,
S. Torrekens,
F. Van Leuven,
J. Vanderleyden, et al.
1995.
Small cysteine-rich antifungal proteins from radish: their role in host defense.
Plant Cell
7:573-588[Abstract].
|
| 21.
|
Wade, D.,
A. Boman,
B. Wahlin,
C. M. Drain,
D. Andreu,
H. G. Boman, and R. B. Merrifield.
1990.
All-D amino acid-containing channel-forming antibiotic peptides.
Proc. Natl. Acad. Sci. USA
87:4761-4765[Abstract/Free Full Text].
|
| 22.
|
Wu, M., and R. E. Hancock.
1999.
Improved derivatives of bactenecin, a cyclic dodecameric antimicrobial cationic peptide.
Antimicrob. Agents Chemother.
43:1274-1276[Abstract/Free Full Text].
|
Applied and Environmental Microbiology, May 2000, p. 1928-1932, Vol. 66, No. 5
0099-2240/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Patrzykat, A., Gallant, J. W., Seo, J.-K., Pytyck, J., Douglas, S. E.
(2003). Novel Antimicrobial Peptides Derived from Flatfish Genes. Antimicrob. Agents Chemother.
47: 2464-2470
[Abstract]
[Full Text]
-
Patrzykat, A., Friedrich, C. L., Zhang, L., Mendoza, V., Hancock, R. E. W.
(2002). Sublethal Concentrations of Pleurocidin-Derived Antimicrobial Peptides Inhibit Macromolecular Synthesis in Escherichia coli. Antimicrob. Agents Chemother.
46: 605-614
[Abstract]
[Full Text]
-
Patrzykat, A., Zhang, L., Mendoza, V., Iwama, G. K., Hancock, R. E. W.
(2001). Synergy of Histone-Derived Peptides of Coho Salmon with Lysozyme and Flounder Pleurocidin. Antimicrob. Agents Chemother.
45: 1337-1342
[Abstract]
[Full Text]